Pharmacogenetics in Jewish populations

Biochemistry, Genetics and Molecular Biology

• CYP2C19 100%
• Pharmacogenetics 100%
• Pharmacogenetic Variant 100%
• Genetics 50%
• Haplotype 50%
• Allele 50%
• Autosomal Recessive Disorder 50%
• Drug Response 50%
• Genetic Architecture 50%
• Drug Metabolism 50%
• CYP2C9 50%
• Bottleneck Population 50%
• CYP2D6 50%
• Vitamin K Epoxide Reductase 50%
• Population Migration 50%
• CYP2C8 50%
• Genomics 50%
• Common Variant 50%

Keyphrases

• Jewish Population 100%
• Pharmacogenetics 100%
• Jews 42%
• Ashkenazi Jews 28%
• CYP2C19 28%
• Racial Groups 28%
• Pharmacogenetic Variants 28%
• Autosomal Recessive 14%
• Gene mutation 14%
• Mendelian Disease Genes 14%
• Long History 14%
• Multi-ethnic 14%
• Disease Susceptibility 14%
• Genetic Architecture 14%
• Loss Function 14%
• Complex Traits 14%
• Genomic Studies 14%
• Cytochrome P450 2D6 (CYP2D6) 14%
• Genetic Determinants 14%
• Founder mutation 14%
• Unique Populations 14%
• N-acetyltransferase 2 (NAT2) 14%
• ATP Binding Cassette Subfamily B Member 1 (ABCB1) 14%
• Population Bottleneck 14%
• Vitamin K Epoxide Reductase 14%
• CYP2C8 14%
• Migration History 14%
• Drug Metabolism Genes 14%
• Migration Population 14%
• Common Diseases 14%
• Geographic Isolation 14%
• Drug Response Variability 14%
• Warfarin Dosing 14%
• Cytochrome P450 2C9 (CYP2C9) 14%